

45

cycloalkylo—, arylO—, heteroarylO—, heterocyclylo—, C₁₋₆ alkylC(=O)O—, -and R^{6a}R^{6b}N(CH₂)_nO—,

n is an integer selected from 1, 2, 3, 4, 5, or 6;

R^{6a} is selected from the group consisting of hydrogen, and

C₁₋₆ alkyl optionally substituted with up to 5 fluoro, and C₁₋₆ alkoxy optionally substituted with up to 5 fluoro;

R^{6b} is selected from the group consisting of alkoxycarbonyl, and C₁₋₆ alkyl optionally substituted with up to 5 fluoro; and

R³ is C₁₋₄ alkyl.

12. The method of claim 11, wherein R³ is isopropyl.


13. A method of treating, preventing, or inhibiting malaria or a disease or disorder associated with malaria or a *Plasmodium* parasite, comprising administering a therapeutically effective amount of the compound of claim 1 to a subject in need thereof.

14. The method of claim 13, wherein the compound is administered intramuscularly, orally, or transdermally.

15. The method of claim 13 further comprising administering to the subject a supplementary active compound, wherein the supplementary active compound is an antimalarial, an antibacterial, or an anti-inflammatory agent.


16. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

17. A compound represented by structural formula 5, or 6,



46

-continued



or a pharmaceutically acceptable equivalent or pharmaceutically acceptable salt of said compound;

wherein R is an optionally substituent selected from the group consisting of alkyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, alkylaryl, heterocyclic rings, and aminoalkyl.

18. The compound of claim 17, wherein R is an optionally substituted substituent selected from the group consisting of alkyl, aryl, aminoalkyl, and heterocyclic ring;

wherein the alkyl substituent or any alkyl portion of the substituents is saturated or unsaturated and/or aliphatic or branched;

or a pharmaceutically acceptable equivalent or pharmaceutically acceptable salt of said compound.

19. The compound of claim 17, wherein R is methyl, ethyl, isopropyl, t-butyl, allyl, benzyl, neopentyl, or phenyl.

20. The compound of claim 17, wherein said compound is represented by structure 6, and wherein R is isopropyl;

or a pharmaceutically acceptable equivalent or pharmaceutically acceptable salt of said compound.

* * * * *